Lawrence C. Trost brings 28 years of experience in nonclinical operations and development, including roles at Cato Research, Triangle Pharmaceuticals, Gilead Sciences, and Chimerix. For the past ten years, he has worked as an independent consultant, providing strategic expertise in study design, management, and reporting to support drug and biologic development from pre-IND through approval. He has extensive experience with the Animal Rule pathway, guiding programs through the unique nonclinical and regulatory requirements it entails. His work also includes regulatory strategy and submissions, development planning, and addressing complex nonclinical challenges such as impurity qualification, bridging studies, and responses to regulatory feedback.

Lawrence has supported a wide range of therapeutic areas—including infectious disease, oncology, cardiovascular, genetic, ocular, autoimmune, respiratory, CNS, and more—spanning diverse modalities and routes of administration. He serves as HOPO’s nonclinical development consultant, supporting the company’s pipeline as it advances HOPO-101.

Back